U.S. Markets closed

Viemed Healthcare Announces Key Data Affecting Patients With Chronic Obstructive Pulmonary Disease Presented by Dr. William Frazier at American College of Chest Physicians Annual Meeting

LAFAYETTE, La., Oct. 22, 2019 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (TSX:VMD.TO and NASDAQ:VMD), a home medical equipment supplier that provides post-acute respiratory care services in the United States, announced that Dr. William Frazier, pulmonologist and Chief Medical Officer for VieMed Healthcare, presented results from the new study, The Impact of Non-Invasive Ventilation (NIV) on Health Cost and Outcomes, at the CHEST Annual Meeting 2019 in New Orleans. Dr. Frazier collaborated with Precision Health Economics on this insightful study exploring the effects of non-invasive ventilation at home (NIVH) for patients with chronic obstructive pulmonary disease (COPD) and chronic respiratory failure (CRF).

COPD is a common disease affecting over 16 million adults in the United States. As COPD progresses, many patients develop CRF, which increases the risks of death and hospitalization, reduces quality of life and increases healthcare costs. While only a few treatment options are available to treat this serious condition, NIVH has shown promise. The use of NIVH is increasing, but fewer than five percent of patients with COPD and CRF are currently receiving this treatment.

The study’s main objectives were to understand the association of NIVH use with the risks of mortality, hospitalizations and ER visits. According to Dr. Frazier, “This study demonstrates that NIVH use in COPD-CRF patients is associated with clinically important and statistically significant reductions in mortality, hospitalization and ER visit rates.”

According to the results of the study, patients receiving NIVH treatment had a 35 percent reduction in mortality as opposed to 47 percent in the untreated population. NIVH treatment also led to a drastic reduction in ER visits and hospitalization.

The clinical implications derived from this study show NIVH should be prescribed by physicians for those patients with COPD-CRF, in order to increase their quality of life and reduce mortality, unnecessary ER visits and costly hospitalizations. The study is currently in peer review for publication.


Viemed, through its indirect wholly-owned subsidiaries Sleep Management, L.L.C. and Home Sleep Delivered, L.L.C., is a home medical equipment supplier that provides post-acute respiratory care services in the United States. Sleep Management, L.L.C. focuses on disease management and improving the quality of life for respiratory patients through clinical excellence, education, and technology. Its service offerings are based on effective home treatment with respiratory care practitioners providing therapy and counseling to patients in their homes using cutting edge technology. Home Sleep Delivered, L.L.C. focuses on providing in-home sleep testing for sleep apnea sufferers. Visit our website at www.viemed.com.

For further information, please contact:

Glen Akselrod
Bristol Capital


Todd Zehnder
Chief Operating Officer
Viemed Healthcare, Inc.


Forward-Looking Statements

Certain statements contained in this press release may constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or “forward-looking information” as such term is defined in applicable Canadian securities legislation (collectively, “forward-looking statements”). Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “potential”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes”, “projects”, or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results “will”, “should”, “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative of these terms or comparable terminology. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance, are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business, market and economic conditions in the regions in which the Company operates; the Company may be subject to significant capital requirements and operating risks; the ability of the Company to implement business strategies and pursue business opportunities; volatility in the market price of shares in the capital of the Company; the Company’s novel business model; the risk that the clinical application of procedures that demonstrate positive results in a study may not be positively replicated or that such test results may not be predictive of actual treatment results;  the state of the capital markets; the availability of funds and resources to pursue operations; decline of reimbursement rates; dependence on few payors; possible new drug discoveries; dependence on key suppliers; granting of permits and licenses in a highly regulated business; competition; low profit market segments; disruptions in or attacks (including cyber-attacks) on the Company's information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; the failure of third parties to comply with their obligations; difficulty integrating newly acquired businesses; the impact of new and changes to, or application of, current laws and regulations; the overall difficult litigation environment; increased competition; changes in foreign currency rates; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the Company’s status as an emerging growth company and a foreign private issuer; and the occurrence of natural and unnatural catastrophic events and claims resulting from such events; as well as those risk factors discussed or referred to in Viemed’s disclosure documents filed with the U.S. Securities and Exchange Commission (the “SEC”) available on the SEC’s website at www.sec.gov, including the Company’s Form 10 filed with the SEC on August 1, 2019, and with the securities regulatory authorities in certain provinces of Canada available at www.sedar.com. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking statements prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.